Stockholders' Equity (Tables)

9 Months Ended

Sep. 30, 2023

Equity [Abstract]

Schedule of common stock warrants

As of September 30, 2023, the Company`s outstanding warrants to purchase shares of common stock consisted of the following:

Issuance Date	Number of Shares of Common Stock Issuable		Exercise Price			Classification	Expiration Date
May 9, 2017		1,696	$	$	226.20	Equity	May 8, 2027
July 19, 2019		2,192	$	$	226.20	Equity	July 18, 2029
		3,888

Schedule of Shares Reserved for Future Issuance

The Company has shares of common stock reserved for future issuances as follows:

	September 30,	December 31,
	2023	2022
Warrants to purchase common stock	3,888	3,888
Common stock options issued and outstanding	1,310,122	114,530
Common stock available for future grants	724,243	18,705
Restricted stock units issued and outstanding	24,782	62,353
Common stock available for ESPP	173,470	3

Schedule of Stock Option Activity

A summary of stock option activity is set forth below (in thousands, except share and per share data):

	Number of Shares Underlying Outstanding Options	Weighted Average Exercise Price		Weighted Average Remaining Contractual Term (in years)		Aggregate Intrinsic Value
Outstanding, December 31, 2022	114,357	$	166.72	8.0	$	1
Options granted	1,271,964	$	5.58
Options exercised	(1,591)	$	6.53
Options forfeited or cancelled or expired	(74,608)	$	48.96
Outstanding, September 30, 2023	1,310,122	$		9.2	$	-
Shares exercisable September 30, 2023	182,188	$	79.83	7.9	$	-
Vested and expected to vest, September 30, 2023	1,310,122	$	17.18	9.2	$	-

Schedule of Restricted Stock Units

A summary of RSU activity is set forth below:

	Number of Shares Underlying Outstanding Restricted Stock			Weighted Average Grant Date Fair Value
Unvested, December 31, 2022		62,340		$	51.65
Released		(31,212	)	$	51.41
Forfeited or cancelled		(6,346	)	$	52.17
Unvested, September 30, 2023		24,782		$	51.83

Summary of Stock-Based Compensation Expense

Total stock-based compensation expense recognized was as follows (in thousands):

	Three Months Ended September 30,				Nine Months Ended September 30,
	2023		2022		2023		2022
Cost of goods sold	$	27	$	97	$	109	$	240
Sales and marketing		258		729		1,229		1,918
Research and development		5		4		21		33
General and administrative		543		1,147		1,846		2,985
Total	$	833	$	1,977	$	3,205	$	5,176

The above stock-based compensation expense related to the following equity-based awards (in thousands):

	Three Months Ended September 30,				Nine Months Ended September 30,
	2023		2022		2023		2022
Stock options	$	674	$	954	$	2,459	$	2,969
RSU		154		852		706		1,982
ESPP		5		171		40		225
Total	$	833	$	1,977	$	3,205	$	5,176

Schedule of Fair Value of Stock Options Estimated Using Weighted-Average Assumptions

The fair value of stock options was estimated using the following weighted-average assumptions:

	Three Months Ended September 30,				Nine Months Ended September 30,
	2023		2022		2023		2022
Expected dividends		0%		0%		0%		0%
Expected volatility		78.10%		72.2%		77.4%-78.1%		70.8%-72.2%
Risk-free interest rate		4.0%		2.8%		4.2%		1.9%-3.0%
Expected term		6 years		6 years		6 years		6 years